Literature DB >> 21896920

Evaluation of the accuracy of a pharmacokinetic dosing program in predicting serum vancomycin concentrations in critically ill patients.

Cecile Aubron1, Carmela E Corallo, Maya O Nunn, Michael J Dooley, Allen C Cheng.   

Abstract

BACKGROUND: Optimization of the timing of appropriate antibiotics is crucial to improve the management of patients in severe sepsis and septic shock. Vancomycin is commonly used empirically in cases of nosocomial infections in critically ill patients. Therefore, early optimization of vancomycin pharmacokinetics is likely to improve outcomes.
OBJECTIVE: To evaluate a pharmacokinetic program to predict serum vancomycin concentrations in accordance with administered dose, weight, height, and creatinine clearance in a critically ill population.
METHODS: We conducted a prospective observational single-center study in a 45-bed intensive care unit (ICU). All patients hospitalized in the ICU requiring intravenous treatment with vancomycin for a suspected infection were enrolled. The modalities of vancomycin therapy and the monitoring of serum concentrations were left to the discretion of the treating clinician. We compared the measured serum vancomycin concentrations with those predicted by the MM-USCPACK program and analyzed the factors influencing the prediction.
RESULTS: Fifty-four intravenous vancomycin courses were administered in 48 critically ill patients over the 3-month study. The precision was considered acceptable, based on a relative precision equal to 8.9% (interquartile range 3.5-18.9%) and the relative bias for all predictions was equal to -1.3%. Overall, 77.3% of predictions were within 20% of observed concentrations; factors correlating with a poorer prediction were a change in renal function, obesity, and the magnitude of organ dysfunction on initiation of vancomycin (expressed by a Systemic Organ Failure Assessment score >11).
CONCLUSIONS: The MM-USCPACK program is a useful and reliable tool for prediction of serum vancomycin concentrations in patients hospitalized in ICU and likely reflects the close monitoring of renal function in this setting. For some patients (more severely ill, obese, or significant change in renal function during vancomycin therapy), predictions were less precise.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21896920     DOI: 10.1345/aph.1Q195

Source DB:  PubMed          Journal:  Ann Pharmacother        ISSN: 1060-0280            Impact factor:   3.154


  5 in total

1.  Pharmacokinetic Assessment of Vancomycin Loading Dose in Critically Ill Patients.

Authors:  Osvaldo Álvarez; Jose Cristian Plaza-Plaza; Manuel Ramirez; Alexis Peralta; Cristián A Amador; Roberto Amador
Journal:  Antimicrob Agents Chemother       Date:  2017-07-25       Impact factor: 5.191

2.  Vancomycin in ICU Patients with Gram-Positive Infections: Initial Trough Levels and Mortality.

Authors:  Nadiyah Alshehri; Anwar E Ahmed; Nagarajkumar Yenugadhati; Sundas Javad; Khalid Al Sulaiman; Hasan M Al-Dorzi; Majed Aljerasiy; Motasim Badri
Journal:  Ther Clin Risk Manag       Date:  2020-10-14       Impact factor: 2.423

3.  Vancomycin-Associated Nephrotoxicity: The Obesity Factor.

Authors:  Stephen W Davies; Jimmy T Efird; Christopher A Guidry; Zachary C Dietch; Rhett N Willis; Puja M Shah; Sara A Hennessy; Robert G Sawyer
Journal:  Surg Infect (Larchmt)       Date:  2015-09-01       Impact factor: 2.150

Review 4.  Vancomycin dosing nomograms targeting high serum trough levels in different populations: pros and cons.

Authors:  Sepideh Elyasi; Hossein Khalili
Journal:  Eur J Clin Pharmacol       Date:  2016-04-27       Impact factor: 2.953

5.  Optimization of time to initial vancomycin target trough improves clinical outcomes.

Authors:  Anthony P Cardile; Christopher Tan; Michael B Lustik; Amy N Stratton; Cristian S Madar; Jun Elegino; Günther Hsue
Journal:  Springerplus       Date:  2015-07-19
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.